DB05044ExperimentalSmall molecule
PSN357 is a glycogen phosphorylase inhibitor (GPI), which is designed to rapidly lower blood glucose levels by preventing glycogen breakdown to glucose in the liver.
- Mechanism
- Curator reviewed
Psn357 is a novel glycogen phosphorylase inhibitor. It reduces night-time systemic glucose levels by reducing the hepatic glucose output that is thought to play a major role in the pathophysiology of type 2 diabetics.
- Primary indication
- Investigated for use/treatment in diabetes mellitus type 2.Curator reviewed
- Code names
- PSN357
Resolves to
Targets
What you can answer from here — as of April 02, 2025
2Protein targetsEach mapped to UniProt, with action and pharmacological actionListed above
Which drugs share a target with PSN357, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account